A lumiperone orally disintegrating tablet composition and its preparation method and application

By adjusting the composition of Lumepiron oral disintegration tablets and adding alkaline diluents and flavoring agents, the bitterness and irritation problems of Lumepiron oral disintegration tablets are solved, and the rapid disintegration and stability of the tablets are achieved, improving the The patient's medication compliance is met with the requirements of the pharmacopoeia.

CN118557536BActive Publication Date: 2024-11-15HQ PHARMA (SHANDONG) CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411027842.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-15
Estimated Expiration
2044-07-30

AI Technical Summary

Technical Problem

The bitterness and irritation of Lumepiron Oral Disintegration Tablets are difficult to mask, and the prior art is difficult to solve this problem, affecting the patient's medication compliance.

Method used

By adjusting the composition of Lumepiron oral collapse tablets, adding alkaline diluents and flavoring agents, combining sweeteners and aromatics, a Lumepiron oral collapse tablet composition is prepared to ensure that the tablets are free of charge when taken Undesirable odor and irritation, and improves the disintegration and stability of the tablets.

Benefits of technology

The poor taste and irritation masking of Lumepiron oral collapse tablets is achieved, which improves the patient's medication compliance, ensures that the tablets are completely disintegrated within 60 seconds, meet the requirements of the pharmacopoeia, and maintains stability for a long time.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118557536B_ABST
    Figure CN118557536B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of pharmaceutical preparations, and specifically relates to a lumeperone orodisintegrating tablet composition and its preparation method and application. By mass percentage, the raw materials of the lumeperone orodisintegrating tablet composition include: 16%-20% of lumeperone tosylate, 40%-60% of hydrophilic diluent, 10%-20% of alkaline diluent, 5%-15% of disintegrant, 3%-9% of flavoring agent, 0.5%-1% of glidant and 0.2%-2% of lubricant. The lumeperone orodisintegrating tablet composition prepared by the present invention has good patient compliance, all disintegrated and passed through the sieve within 60 seconds, and has good storage stability and low impurity content.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of pharmaceutical preparations, and in particular relates to a lumepirone orodisintegrating tablet composition and a preparation method and application thereof. Background Art

[0002] Lumeperone is an atypical antipsychotic drug. Based on the target of lumepirone and the binding rate with dopamine D2 receptors, it is a second-generation antipsychotic drug with unique properties. Unlike other schizophrenia drugs, lumepirone has partial agonist activity on presynaptic dopamine D2 receptors, which reduces the release of presynaptic dopamine, and also has an antagonist effect on postsynaptic dopamine D2 receptors. These characteristics enable lumepirone to effectively reduce dopamine signaling. Lumeperone also targets dopamine D1 receptors. The secondary auxiliary effect of D1 receptor activation is to increase the phosphorylation of glutamatergic N-methyl-D-aspartate (NMDA) GluN2B receptors, and NMDA-mediated glutamate signaling channels play an important role in the impairment of schizophrenia patients. Lumeperone can regulate 5-hydroxytryptamine by inhibiting 5-hydroxytryptamine transporter proteins and acts as a 5-HA2 receptor antagonist, which is used to treat behavioral disorders in schizophrenia and other neurological diseases.

[0003] Due to the uncertainty of the onset time of schizophrenia and the poor compliance of patients when the disease occurs, it is necessary to administer the drug to the patients as soon as possible. Therefore, it is very necessary to prepare lumepirone into an orally disintegrating tablet that is easy to carry, easy to take and can take effect quickly.

[0004] Oral solid rapid-release drug preparations, especially oral rapid-dissolving and rapid-disintegrating drug tablets, are characterized by the fact that the tablets can be placed on the tongue or other parts of the mouth and can be quickly dissolved or disintegrated without taking water. Some drugs enter the gastrointestinal tract through natural swallowing movements, and some drugs are absorbed through the oral mucosa and enter the systemic circulation. Its advantages are rapid drug release, rapid onset of action, and high bioavailability. This type of solid rapid-release drug preparation is particularly suitable for patients with dysphagia, the elderly and children, and patients without drinking water. Orally disintegrating tablets have the advantages of convenient medication and reliable effects.

[0005] Chinese invention patent application CN116919907A discloses a lumepirone orodisintegrating tablet and a preparation method thereof. The lumepirone orodisintegrating tablet mainly comprises active ingredients lumepirone, mannitol, cross-linked sodium carboxymethyl cellulose, talcum powder, magnesium stearate and a flavoring agent. The preparation method is as follows: (1) pulverizing lumepirone to obtain a powder with an average particle size of 15 μm, grinding the flavoring agent and passing it through a 60-mesh sieve, and passing the mannitol through a 60-mesh sieve for later use; (2) mixing lumepirone and part of the hydrophilic diluent by an equal amount incremental mixing method, and then adding cross-linked sodium carboxymethyl cellulose and the remaining hydrophilic diluent and flavoring agent and mixing them evenly; (3) adding the talcum powder and lubricant to the mixed drug obtained in step (2), sieving and mixing, and tableting to obtain the lumepirone orodisintegrating tablet.

[0006] However, the raw material of lumiperone itself is extremely bitter and irritating to the mouth. There is no public report on the technology of masking the bad taste of lumiperone in the prior art, and conventional taste-masking methods are difficult to mask its bitterness and irritation. Summary of the invention

[0007] In view of the bitterness and irritation of orally disintegrating tablets of lumepirone in the prior art, the present invention provides a composition of orally disintegrating tablets of lumepirone and a preparation method and application thereof. The orally disintegrating tablets of lumepirone prepared by the present invention can not only mask the bad taste, but also have stable properties and good quality, meet the relevant requirements of orally disintegrating tablet preparations, and can improve the medication compliance of schizophrenia patients.

[0008] The present invention is achieved through the following technical solutions:

[0009] A lumiperone orodisintegrating tablet composition, wherein the raw materials of the lumiperone orodisintegrating tablet composition include, by mass percentage: 16%-20% of lumiperone tosylate, 40%-60% of a hydrophilic diluent, 10%-20% of an alkaline diluent, 5%-15% of a disintegrant, 3%-9% of a flavoring agent, 0.5%-1% of a glidant, and 0.2%-2% of a lubricant.

[0010] Preferably, the particle size D90 of the lumepirone tosylate is less than 10 μm, and the hydrophilic diluent is selected from one or more of sorbitol, mannitol, lactose and microcrystalline cellulose.

[0011] Further preferably, the hydrophilic diluent is a mixture of mannitol and lactose, and the mass ratio of mannitol to lactose is 1:2-4.

[0012] Preferably, the alkaline diluent is selected from one or more of calcium phosphate, anhydrous calcium hydrogen phosphate, sodium bicarbonate, potassium hydroxide, magnesium hydroxide, magnesium trisilicate, disodium hydrogen phosphate and arginine.

[0013] Further preferably, the alkaline diluent is a mixture of calcium phosphate and anhydrous calcium hydrogen phosphate, and the mass ratio of the calcium phosphate to the anhydrous calcium hydrogen phosphate is 1.3-1.5:1.

[0014] Preferably, the disintegrant is selected from one or more of pregelatinized starch, cross-linked sodium carboxymethyl cellulose, cross-linked polyvinylpyrrolidone, sodium carboxymethyl starch and polyvinylpyrrolidone.

[0015] Preferably, the flavoring agent includes a sweetener and a flavoring agent, the sweetener includes a natural sweetener and an artificial sweetener, the natural sweetener is selected from one or more of xylitol, glucose, sucrose, maltose, stevioside, dextrose, fructose, liquid glucose and isomaltose, the artificial sweetener is selected from one or more of saccharin, sodium cyclamate, sucralose, acesulfame potassium, aspartame and neotame, and the flavoring agent is selected from one or more of strawberry flavor, orange flavor, vanilla flavor and cocoa flavor.

[0016] Preferably, the glidant is selected from one or more of colloidal silicon dioxide, talc, magnesium stearate, sodium stearyl fumarate and glyceryl behenate.

[0017] Preferably, the lubricant is selected from one or more of magnesium stearate, sodium stearyl fumarate and glyceryl behenate.

[0018] The present invention also relates to a method for preparing the above-mentioned lumiperone orally disintegrating tablet composition, comprising the following steps:

[0019] (1) Sieve lumepirone tosylate and flavoring agent separately and set aside;

[0020] (2) mixing lumepirone tosylate and a hydrophilic diluent by an equal amount stepwise mixing method, and then adding a disintegrant, a flavoring agent, an alkaline diluent and the remaining hydrophilic diluent and mixing them uniformly to obtain a mixture 1;

[0021] (3) Add a glidant to the mixture 1, sieve and mix well, then add a lubricant and mix thoroughly, and compress the mixture into tablets to obtain the lumepirone orally disintegrating tablet composition.

[0022] Preferably, in step (1), the pellets are sieved with a 60-80 mesh screen, and in step (3), the pellets are sieved with a 40-45 mesh screen, and the hardness of the pellets is 20-60N.

[0023] The present invention also relates to the use of the above-mentioned lumepirone orodisintegrating tablet composition in the preparation of antipsychotic drugs.

[0024] During the research and development process, the inventors unexpectedly discovered that in the preparation process of orally disintegrating tablets with lumiperone as the active ingredient, when a certain amount of alkaline excipients is included in the prescription composition, the unpleasant taste of lumiperone can be well masked. At the same time, the obtained orally disintegrating tablets have stable properties and good quality, meet the relevant requirements of the 2020 edition of the "Chinese Pharmacopoeia" for orally disintegrating tablet preparations, and can improve the medication compliance of schizophrenia patients.

[0025] Compared with the prior art, the present invention has the following beneficial effects:

[0026] (1) The orodisintegrating lumepirone tablet composition prepared by the present invention has good patient compliance, and patients do not experience any bad smell or irritation when taking the orodisintegrating lumepirone tablet.

[0027] (2) The orodisintegrating tablet compositions of lumepirone of the present invention were tested according to the requirements of the pharmacopoeia and all disintegrated and passed through the sieve within 60 seconds, and had good storage stability. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 is a dissolution curve of the lumepirone orally disintegrating tablet composition in Example 5 of the present invention;

[0029] Figure 2 It is the dissolution curve of the control preparation. DETAILED DESCRIPTION

[0030] The present invention will be further described in detail below in conjunction with specific examples. The following examples are not intended to limit the present invention, but are only intended to illustrate the present invention. The experimental methods used in the following examples are generally conventional, unless otherwise specified, and the materials, reagents, etc. used in the following examples are commercially available, unless otherwise specified.

[0031] Example 1

[0032] A lumiperone orodisintegrating tablet composition, the raw materials and dosages thereof are shown in Table 1.

[0033] Table 1 Raw materials and dosage

[0034]

[0035] The preparation method of the lumiperone orally disintegrating tablet composition is as follows:

[0036] (1) Pass lumepirone tosylate and sucralose through a 80-mesh sieve respectively and set aside;

[0037] (2) Lumiperone tosylate and part of the hydrophilic diluent (mannitol and lactose) are mixed uniformly by an equal amount incremental mixing method, and then cross-linked polyvinylpyrrolidone, sucralose, calcium phosphate and the remaining hydrophilic diluent (mannitol and lactose) are added and mixed uniformly to obtain a mixture 1;

[0038] (3) Add colloidal silicon dioxide to the mixture 1, sieve through a 40-mesh sieve and mix well, then add magnesium stearate and mix thoroughly, and compress the mixture into tablets to a hardness of 20N to obtain the lumepirone orally disintegrating tablet composition.

[0039] Example 2

[0040] A lumiperone orodisintegrating tablet composition, the raw materials and dosages thereof are shown in Table 2.

[0041] Table 2 Raw materials and dosage

[0042]

[0043] The preparation method of the lumiperone orally disintegrating tablet composition is as follows:

[0044] (1) Pass lumepirone tosylate and sucralose through a 60-mesh sieve respectively and set aside;

[0045] (2) Lumiperone tosylate and part of the hydrophilic diluent (mannitol and lactose) are mixed uniformly by an equal amount stepwise mixing method, and then cross-linked polyvinylpyrrolidone, sucralose, calcium phosphate and the remaining hydrophilic diluent (mannitol and lactose) are added and mixed uniformly to obtain a mixture 1;

[0046] (3) Add colloidal silicon dioxide to the mixture 1, sieve through a 40-mesh sieve and mix well, then add magnesium stearate and mix thoroughly, and compress the mixture into tablets until the hardness reaches 60N to obtain the lumepirone orally disintegrating tablet composition.

[0047] Example 3

[0048] A lumiperone orodisintegrating tablet composition, the raw materials and dosages thereof are shown in Table 3.

[0049] Table 3 Raw materials and dosage

[0050]

[0051] The preparation method of the lumiperone orally disintegrating tablet composition is as follows:

[0052] (1) Pass lumepirone tosylate and sucralose through a 60-mesh sieve respectively and set aside;

[0053] (2) Lumiperone tosylate and part of the hydrophilic diluent (mannitol and lactose) are mixed uniformly by an equal amount incremental mixing method, and then cross-linked polyvinylpyrrolidone, sucralose, calcium phosphate and the remaining hydrophilic diluent (mannitol and lactose) are added and mixed uniformly to obtain a mixture 1;

[0054] (3) Add colloidal silicon dioxide to the mixture 1, sieve through a 45-mesh sieve and mix well, then add magnesium stearate and mix thoroughly, and compress the mixture into tablets to a hardness of 40N to obtain the lumepirone orally disintegrating tablet composition.

[0055] Example 4

[0056] A lumiperone orodisintegrating tablet composition, the raw materials and dosages thereof are shown in Table 4.

[0057] Table 4 Raw materials and dosage

[0058]

[0059] The preparation method of the lumiperone orally disintegrating tablet composition is as follows:

[0060] (1) Pass lumepirone tosylate and sucralose through a 80-mesh sieve respectively and set aside;

[0061] (2) Lumiperone tosylate and part of the hydrophilic diluent (mannitol and lactose) are mixed uniformly by an equal amount stepwise mixing method, and then cross-linked polyvinylpyrrolidone, sucralose, anhydrous calcium hydrogen phosphate and the remaining hydrophilic diluent (mannitol and lactose) are added and mixed uniformly to obtain a mixture 1;

[0062] (3) Add colloidal silicon dioxide to the mixture 1, sieve through a 40-mesh sieve and mix well, then add magnesium stearate and mix thoroughly, and compress the mixture into tablets to a hardness of 40N to obtain the lumepirone orally disintegrating tablet composition.

[0063] Example 5

[0064] A lumiperone orodisintegrating tablet composition, the raw materials and dosages thereof are shown in Table 5.

[0065] Table 5 Raw materials and dosage

[0066]

[0067] The preparation method of the lumiperone orally disintegrating tablet composition is as follows:

[0068] (1) Pass lumepirone tosylate and sucralose through a 80-mesh sieve respectively and set aside;

[0069] (2) Lumiperone tosylate and part of the hydrophilic diluent (mannitol and lactose) are mixed uniformly by an equal amount stepwise mixing method, and then cross-linked polyvinylpyrrolidone, sucralose, calcium phosphate, anhydrous calcium hydrogen phosphate and the remaining hydrophilic diluent (mannitol and lactose) are added and mixed uniformly to obtain a mixture 1;

[0070] (3) Add colloidal silicon dioxide to the mixture 1, sieve through a 40-mesh sieve and mix well, then add magnesium stearate and mix thoroughly, and compress the mixture into tablets to a hardness of 40N to obtain the lumepirone orally disintegrating tablet composition.

[0071] Comparative Example 1

[0072] A lumiperone orodisintegrating tablet composition, the raw materials and dosages thereof are shown in Table 6.

[0073] Table 6 Raw materials and dosage

[0074]

[0075] The preparation method of the above-mentioned lumiperone orally disintegrating tablet composition is as follows:

[0076] (1) According to the molar ratio of the raw material drug (lumeperone tosylate): β-cyclodextrin = 1:2, β-cyclodextrin was added to 200 mL of purified water at 50°C to dissolve, and lumeperone tosylate was added to the cyclodextrin solution, stirred for 5 hours to obtain a drug-containing solution, and allowed to stand overnight. The solution was filtered and the precipitate was dried to obtain the lumeperone cyclodextrin inclusion complex;

[0077] (2) The lumepirone cyclodextrin inclusion compound is sieved through an 80-mesh sieve and crushed, and then mixed with the remaining auxiliary materials, and tableted to a hardness of 40N to obtain the lumepirone orally disintegrating tablet composition.

[0078] Comparative Example 2

[0079] A lumiperone orodisintegrating tablet composition, the raw materials and dosages thereof are shown in Table 7.

[0080] Table 7 Raw materials and dosage

[0081]

[0082] The preparation method of the above-mentioned lumiperone orally disintegrating tablet composition:

[0083] (1) Pass lumepirone tosylate and sucralose through a 80-mesh sieve respectively and set aside;

[0084] (2) Lumiperone tosylate and part of the hydrophilic diluent (mannitol and lactose) are mixed uniformly by an equal amount stepwise mixing method, and then cross-linked polyvinylpyrrolidone, sucralose, menthol and the remaining hydrophilic diluent (mannitol and lactose) are added and mixed uniformly to obtain a mixture 1;

[0085] (3) Add colloidal silicon dioxide to the mixture 1, sieve through a 40-mesh sieve and mix well, then add magnesium stearate and mix thoroughly, and compress the mixture into tablets to a hardness of 40N to obtain the lumepirone orally disintegrating tablet composition.

[0086] Comparative Example 3

[0087] A lumepirone orodisintegrating tablet composition, the raw materials and dosages thereof are shown in Table 8. Compared with Example 5, the total weight is the same, but the ratio of raw materials and auxiliary materials is different.

[0088] Table 8 Raw materials and dosage

[0089]

[0090] The preparation method of the above-mentioned lumidperone orally disintegrating tablet composition is consistent with that of Example 5.

[0091] Comparative Examples 4-5

[0092] The raw materials and dosage of the lumiperone orally disintegrating tablet composition of Comparative Example 4-5 are shown in Table 9.

[0093] Table 9 Raw materials and dosage

[0094]

[0095] The preparation method of the above-mentioned lumidperone orally disintegrating tablet composition is consistent with that of Example 5.

[0096] Effect test

[0097] Test Example 1 Taste Evaluation

[0098] In order to evaluate the irritation intensity of the above-mentioned lumepirone orodisintegrating tablet composition, a program was designed and a volunteer oral irritation experience test was conducted to appropriately evaluate its oral irritation inhibition effect, as follows:

[0099] Test plan: A total of 10 male and female volunteers aged 20-40 were selected to randomly conduct taste tests on the embodiments and comparative examples, and the oral irritation sensation was scored based on the taste.

[0100] Scoring criteria:

[0101] 85-100 points: no irritation, no bitterness or almost no bitterness, no irritation;

[0102] 70-85 points: slightly bitter or slightly irritating, acceptable;

[0103] 55-70 points: Bitter or irritating, but not strong and unacceptable;

[0104] <55 points: The bitterness or irritation is strong and unacceptable.

[0105] The specific taste test results are shown in Table 10 below.

[0106] Table 10 Taste test results

[0107]

[0108] The results showed that the testers had good acceptance of Examples 1-3 and Comparative Example 2, with obvious sweetness, good taste, and disintegration in the mouth within 10 seconds without any gritty feeling. Comparative Example 4 had a more obvious bitter feeling, and although the taste of Comparative Example 5 was acceptable, it had a gritty feeling in the mouth.

[0109] Test Example 2 Disintegration Time

[0110] Test method: Immerse in a 1000mL cup containing 900mL of water at 37℃±1℃. Adjust the water level so that the screen is 15mm±1mm below the water surface when the stainless steel tube is at its lowest position. Take one tablet of this product and place it in the above stainless steel tube for inspection. It should completely disintegrate and pass through the screen within 60 seconds. If there is a small amount of light floating or adhering to the inner wall of the stainless steel tube or the screen, but there is no hard core, it can be considered as meeting the regulations. Repeat the measurement of 6 tablets, and all should meet the regulations. If 1 tablet does not meet the regulations, another 6 tablets should be taken for retest, and all should meet the regulations. The test results are shown in Table 11.

[0111] Table 11 Disintegration time test results

[0112]

[0113] The results showed that the average disintegration time of Examples 1-5 and Comparative Examples 1, 4, and 5 all met the requirements of the Pharmacopoeia.

[0114] Test Example 3 Dissolution curve test results

[0115] The reference product (RLD), Lumateperone tosylate capsule (Caplyta), strength 42 mg (calculated as Lumateperone), licensee Intra-Cellular Therapies Inc.

[0116] Dissolution method:

[0117] ①0.1M HCl medium--paddle method + spiral sedimentation basket, 50rpm, 500mL; ②pH4.5 medium--basket method, 100rpm, 500mL; ③pH6.8 medium--basket method, 100rpm, 500mL. The dissolution medium temperature was kept constant at 37℃±0.5℃ during the test.

[0118] The test results of the lumepirone orally disintegrating tablet composition and the reference preparation (RLD) in Example 5 are as follows: Figure 1 , Figure 2 As shown in Table 12.

[0119] Table 12 Dissolution curve test results

[0120]

[0121] Combining the dissolution data of the reference preparation in the table with the dissolution data of Example 5, it can be seen that the preparation in Example 5 and the reference preparation both exhibit rapid dissolution in 0.1M HCl, pH 4.5 medium, and their dissolution behaviors are similar. In the pH 6.8 medium, both the preparation in Example 5 and the reference preparation exhibit incomplete dissolution.

[0122] The dissolution curve test results of the lumepirone orally disintegrating tablet compositions in Comparative Examples 1 and 4-5 in a pH 4.5 medium are shown in Table 13.

[0123] Table 13 Dissolution curve test results of comparative examples 1, 4-5

[0124]

[0125] Through the dissolution test in pH 4.5 medium, comparative examples 1, 4, and 5 did not achieve rapid dissolution, and were not similar to the dissolution of the reference preparation.

[0126] Test Example 4: Results of Stability Test of Related Substances

[0127] The conditions of the accelerated experiment were: 40℃±2℃, 75%RH±5%RH, and the observation period was 6 months.

[0128] Test method: Use high performance liquid chromatography, the chromatographic column is YMC-Pack Pro C18 4.6×150mm, 3μm, the mobile phase A is 25mmol / L potassium dihydrogen phosphate solution (adjusted to pH2.5 with phosphoric acid), the mobile phase B is acetonitrile:methanol (v / v) (1:1), and 5μL is injected at a flow rate of 1.0mL / min.

[0129] The test results are shown in Table 14.

[0130] Table 14 Test results of stability of relevant substances

[0131]

[0132] Conclusion: The impurities in Example 5 are relatively stable and far below the qualified standard. Although Comparative Examples 1, 4, and 5 also meet the standards, the impurity levels are relatively high.

[0133] The above detailed description is a specific description of one feasible embodiment of the present invention. The embodiment is not intended to limit the patent scope of the present invention. Any equivalent implementation or modification that does not deviate from the present invention should be included in the scope of the technical solution of the present invention.

Claims

1. A lumiperone orodisintegrating tablet composition, characterized in that: The raw materials of the lumepirone orodisintegrating tablet composition are as follows: 16%-20% lumepirone tosylate, 40%-60% hydrophilic diluent, 10%-20% alkaline diluent, 5%-15% disintegrant, 3%-9% flavoring agent, 0.5%-1% glidant and 0.2%-2% lubricant, calculated by mass percentage. The hydrophilic diluent is a mixture of mannitol and lactose, and the mass ratio of mannitol to lactose is 1:2-4; The alkaline diluent is a mixture of calcium phosphate and anhydrous calcium hydrogen phosphate, and the mass ratio of the calcium phosphate to the anhydrous calcium hydrogen phosphate is 1.3-1.5:1; The flavoring agent is sucralose; the disintegrant is cross-linked polyvinylpyrrolidone; the glidant is colloidal silicon dioxide; and the lubricant is magnesium stearate.

2. The orodisintegrating tablet composition of lumepirone according to claim 1, characterized in that: The particle size D90 of the lumepirone tosylate is less than 10 μm.

3. A method for preparing the lumepirone orally disintegrating tablet composition according to any one of claims 1 to 2, characterized in that: The following steps are involved: (1) Sieve lumepirone tosylate and flavoring agent separately and set aside; (2) mixing lumepirone tosylate and a hydrophilic diluent by an equal amount stepwise mixing method, and then adding a disintegrant, a flavoring agent, an alkaline diluent and the remaining hydrophilic diluent and mixing them uniformly to obtain a mixture 1; (3) Add a glidant to the mixture 1, sieve and mix well, then add a lubricant and mix thoroughly, and compress the mixture into tablets to obtain the lumepirone orally disintegrating tablet composition.

4. The preparation method according to claim 3, characterized in that: In step (1), the pellets are sieved with a 60-80 mesh screen, and in step (3), the pellets are sieved with a 40-45 mesh screen. The hardness of the pellets is 20-60N.

5. Use of the lumepirone orodisintegrating tablet composition according to any one of claims 1 to 2 in the preparation of antipsychotic drugs.